trending Market Intelligence /marketintelligence/en/news-insights/trending/ExNFLMloPSbv9GEuDKtVYg2 content esgSubNav
In This List

Moody's: FDA approval of MS drug generic is credit positive for Mylan

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022

Blog

Insight Weekly: Reviving nuclear power; 2023 outlook for US financials; PE funds fuel EV sector


Moody's: FDA approval of MS drug generic is credit positive for Mylan

Moody's said the U.S. Food & Drug Administration's approval of Mylan NV's generic version of multiple sclerosis treatment Copaxone is a credit positive for the company.

The approval is credit positive for Mylan because it represents a significant opportunity for additional growth in earnings and cash flow through 2018.

Moody's said the approval is credit negative for Teva Pharmaceutical Industries Ltd., since the launch of Mylan's generics will result in significant declines in Teva's largest product starting in the fourth quarter of 2017.

There are no changes to the ratings or outlooks of the companies.